Literature DB >> 35393609

Identifying Acute Neuropsychiatric Events in Children and Adolescents.

James W Antoon1,2, James A Feinstein3,4, Carlos G Grijalva5, Yuwei Zhu6, Emily Dickinson3,4, Justine C Stassun1,2, Jakobi A Johnson1,2, Mert Sekmen1,2, Yasas C Tanguturi7, James C Gay8, Derek J Williams1,2.   

Abstract

OBJECTIVES: The objective of this study was to develop and validate an approach to accurately identify incident pediatric neuropsychiatric events (NPEs) requiring hospitalization by using administrative data.
METHODS: We performed a cross-sectional, multicenter study of children 5 to 18 years of age hospitalized at two US children's hospitals with an NPE. We developed and evaluated 3 NPE identification algorithms: (1) primary or secondary NPE International Classification of Diseases, 10th Revision diagnosis alone, (2) NPE diagnosis, the NPE was present on admission, and the primary diagnosis was not malignancy- or surgery-related, and (3) identical to algorithm 2 but without requiring the NPE be present on admission. The positive predictive value (PPV) of each algorithm was calculated overall and by diagnosis field (primary or secondary), clinical significance, and NPE subtype.
RESULTS: There were 1098 NPE hospitalizations included in the study. A total of 857 confirmed NPEs were identified for algorithm 1, yielding a PPV of 0.78 (95% confidence interval [CI] 0.76-0.80). Algorithm 2 (n = 846) had an overall PPV of 0.89 (95% CI 0.87-0.91). For algorithm 3 (n = 938), the overall PPV was 0.86 (95% CI 0.83-0.88). PPVs varied by diagnosis order, NPE clinical significance, and subtype. The PPV for critical clinical significance was 0.99 (0.97-0.99) for all 3 algorithms.
CONCLUSIONS: We identified a highly accurate method to identify neuropsychiatric adverse events in children and adolescents. The use of these approaches will improve the rigor of future studies of NPE, including the necessary evaluations of medication adverse events, infections, and chronic conditions.
Copyright © 2022 by the American Academy of Pediatrics.

Entities:  

Mesh:

Year:  2022        PMID: 35393609      PMCID: PMC9058193          DOI: 10.1542/hpeds.2021-006329

Source DB:  PubMed          Journal:  Hosp Pediatr        ISSN: 2154-1671


  21 in total

1.  Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012.

Authors:  Keith B Hoffman; Andrea Demakas; Colin B Erdman; Mo Dimbil; P Murali Doraiswamy
Journal:  BMJ       Date:  2013-07-23

Review 2.  Association between leukotriene-modifying agents and suicide: what is the evidence?

Authors:  Glen T Schumock; Todd A Lee; Min J Joo; Robert J Valuck; Leslie T Stayner; Robert D Gibbons
Journal:  Drug Saf       Date:  2011-07-01       Impact factor: 5.606

3.  A Boxed Warning for Montelukast: The FDA Perspective.

Authors:  Katherine Clarridge; Stacy Chin; Efe Eworuke; Sally Seymour
Journal:  J Allergy Clin Immunol Pract       Date:  2021-03-17

4.  The Relationship Between Oseltamivir and Suicide in Pediatric Patients.

Authors:  Rachel Harrington; Sruthi Adimadhyam; Todd A Lee; Glen T Schumock; James W Antoon
Journal:  Ann Fam Med       Date:  2018-03       Impact factor: 5.166

5.  Factors Associated With COVID-19 Disease Severity in US Children and Adolescents.

Authors:  James W Antoon; Carlos G Grijalva; Cary Thurm; Troy Richardson; Alicen B Spaulding; Ronald J Teufel; Mario A Reyes; Samir S Shah; Julianne E Burns; Chén C Kenyon; Adam L Hersh; Derek J Williams
Journal:  J Hosp Med       Date:  2021-10       Impact factor: 2.899

Review 6.  Adverse effects of antiepileptic drugs.

Authors:  Piero Perucca; Frank G Gilliam
Journal:  Lancet Neurol       Date:  2012-07-24       Impact factor: 44.182

7.  Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation.

Authors:  Chris Feudtner; James A Feinstein; Wenjun Zhong; Matt Hall; Dingwei Dai
Journal:  BMC Pediatr       Date:  2014-08-08       Impact factor: 2.125

Review 8.  An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency.

Authors:  Andrew C Bennett; Charles L Bennett; Bartlett J Witherspoon; Kevin B Knopf
Journal:  Expert Opin Drug Saf       Date:  2019-09-18       Impact factor: 4.250

9.  Discontinuation of levetiracetam because of behavioral side effects: a case-control study.

Authors:  J R White; T S Walczak; I E Leppik; J Rarick; T Tran; T E Beniak; D J Matchinsky; R J Gumnit
Journal:  Neurology       Date:  2003-11-11       Impact factor: 9.910

10.  Metronidazole-induced neurotoxicity.

Authors:  Danica Quickfall; Nick Daneman; Adam A Dmytriw; David N Juurlink
Journal:  CMAJ       Date:  2021-10-25       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.